For research use only. Not for therapeutic Use.
Cbl-b-IN-1 (example 519) is a Cbl-b inhibitor, extracted from patent WO2019148005A1, with an IC50 <100 nM[1].
Catalog Number | I015215 |
CAS Number | 2368841-84-1 |
Synonyms | 4-(5-azaspiro[2.4]heptan-5-ylmethyl)-6-cyclopropyl-N-[3-[3-[(4-methyl-1,2,4-triazol-3-yl)methyl]oxetan-3-yl]phenyl]pyridine-2-carboxamide |
Molecular Formula | C29H34N6O2 |
Purity | ≥95% |
InChI | InChI=1S/C29H34N6O2/c1-34-19-30-33-26(34)14-29(17-37-18-29)22-3-2-4-23(13-22)31-27(36)25-12-20(11-24(32-25)21-5-6-21)15-35-10-9-28(16-35)7-8-28/h2-4,11-13,19,21H,5-10,14-18H2,1H3,(H,31,36) |
InChIKey | VXMQSDNIOKDJHW-UHFFFAOYSA-N |
SMILES | CN1C=NN=C1CC2(COC2)C3=CC(=CC=C3)NC(=O)C4=CC(=CC(=N4)C5CC5)CN6CCC7(C6)CC7 |
Reference | [1]. BARSANTI PAUL A (US), et al. INHIBITORS OF CBL-B AND METHODS OF USE THEREOF. WO/2019/148005A1. |